ProCE Banner Activity

ALPINE: Final Analysis of Zanubrutinib vs Ibrutinib for Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Slideset Download

Zanubrutinib demonstrated superior ORR and PFS compared with ibrutinib in patients with R/R CLL/SLL.

Released: December 19, 2022

Expiration: December 18, 2023

No longer available for credit.
Begin Activity

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

AbbVie

Amgen

AstraZeneca

Epizyme

GSK

Incyte Corporation

Jazz Pharmaceuticals

Karyopharm Therapeutics Inc.

Novartis Pharmaceuticals Corporation

Sanofi

Seagen